Pre-market Hot Trades in US Stocks

AMD is up 3.65% in pre-market trading. Based on recent key news:

1. On July 28, AMD reached a cooperation agreement with Core Scientific to obtain 500 megawatts of computing power resources, which can be expanded to 2.5 gigawatts in the future. This news caused AMD's pre-market stock price to drop by about 5%. Source: Benzinga

2. On July 30, Susquehanna raised AMD's target price, expecting its server CPU business to bring upward potential, leading to a pre-market stock price increase of over 6%. Source: Benzinga

3. On July 31, AMD's free cash flow in the second quarter plummeted by 91% year-on-year, causing the stock price to drop by 8% after the earnings report was released. Source: Benzinga AI industry demand is strong, with capital flowing into the semiconductor sector.

Taiwan Semiconductor is up 3.64% in pre-market trading. Based on recent key news:

1. On July 31, the Taiwan stock market made a strong comeback, with Taiwan Semiconductor leading the charge, the index surged by 2,962 points during the session, contributing over 1,600 points, and electronic weighted stocks ignited, driving a strong rebound in the AI supply chain. Source: Zhitong Finance

2. On July 30, Taiwan Semiconductor's stock price fluctuated, with post-market trading showing paired transactions above the spot price, easing foreign selling pressure, and the market is watching whether the stock price can bottom out and recover. Source: Wall Street Insight

3. On July 28, concerns about AI investment returns increased, leading to a drop of 2,030 points in the Taiwan stock market, and Taiwan Semiconductor's ADR fell by 1.07%, but the trading value of Taiwan stock ETFs exceeded NT$100 billion, indicating active buying on dips. Source: Jinshi Data Technology stocks rebounded, and market confidence recovered.

Top Gainers in Pre-market US Stocks

Microbus is up 305.67% in pre-market trading. Based on recent key news:

1. On July 30, Wetour Robotics announced a share consolidation plan with a consolidation ratio of 1 to 100, expected to take effect on August 3. This move may lead to a reassessment of its stock by the market, affecting stock price volatility. Source: SEC Announcement

2. On July 29, Fermi and Galaxy Digital faced uncertainty amid changes in cryptocurrency regulation, causing fluctuations in investor interest in risk assets, affecting related market sentiment. Source: MarketWatch

3. On July 29, Sprott Physical Silver Trust continued to serve as a barometer for inflation expectations and industrial demand, reflecting the market's focus on physical assets. Source: CNBC Changes in cryptocurrency regulation affect market sentiment.

Focus Universal is up 276.60% in pre-market trading. Based on recent key news:

1. On July 27, Focus Universal Inc. released original content, leading to a significant increase in stock price. The company disclosed important information in the announcement, driving strong market interest in its stock, resulting in a pre-market surge of 276.60% for Focus Universal
2. Recently, there have been no other important news. The market reacted strongly to the company's announcement, with active trading.

Replimune pre-market rose 131.25%. Based on recent key news:

1. On July 31, Replimune's RP1 drug received support at the FDA advisory committee meeting, driving the stock price significantly higher. The FDA advisory committee voted in favor of the trial results of RP1 in advanced melanoma, and the FDA is expected to make a decision on August 2. This news triggered a positive market reaction, with the stock price rising 131.25% in pre-market. Source: Reuters

2. On July 28, FDA staff raised questions about the effectiveness of Replimune's RP1 drug, leading to a decline in the stock price. The FDA noted in its review documents that the clinical trials of RP1 failed to provide sufficient evidence of its effectiveness, resulting in a 21% drop in the stock price in pre-market. Source: Reuters

3. On July 30, Replimune announced that the FDA advisory committee's review results for RP1 were positive, further driving the stock price up. The company stated that the FDA's target action date is August 2, and the market is optimistic about this. Source: Reuters The biopharmaceutical industry faces regulatory challenges and high volatility